Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Martin R. Wilkins(Hammersmith Hospital), J. Simon R. Gibbs(Imperial College London), Alexander Stefanidis(Leicester Royal Infirmary), Nina Tunariu(Leicester Royal Infirmary), Raad Mohiaddin(Leicester Royal Infirmary), Gideon Paul(Leicester Royal Infirmary), Wendy Gin‐Sing, Dudley J. Pennell(The Royal Free Hospital), Leong L. Ng(Leicester Royal Infirmary), Winston Banya(Leicester Royal Infirmary), Mark A. Westwood(Leicester Royal Infirmary), Petros Nihoyannopoulos(Imperial College London), Julian Strange(NIHR Bristol Cardiovascular Biomedical Research Unit)
Cited by 381
Related Papers
Bulletin of the World Health Organization
|Bulletin of the World Health Organization|2001|7.2k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k